HBM Holdings Ltd

02142

Company Profile

  • Business description

    HBM Holdings Ltd is a clinical-stage biopharmaceutical company engaged in the discovery and development of differentiated antibody therapeutics in immunology and oncology disease areas. Its products under development are Batoclimab, for the treatment of a wide spectrum of autoimmune diseases; Tanfanercept, for the treatment of moderate-to-severe dry eye disease (DED); HBM4003; HBM9378, to prevent and treat COVID-19, the pandemic respiratory disease caused by the SARS-CoV-2 virus; HBM7008; and others. Its geographical segments are Mainland China, United States, Europe, and others. The majority of the revenue for the firm is generated from the United States.

  • Contact

    218 Xinghu Street
    Suite 202, Building A3, Suzhou Industrial Park
    Suzhou215123
    CHN

    T: +86 51265790025

    https://www.harbourbiomed.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2025

    Employees

    183

Stocks News & Analysis

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,741.9026.70-0.30%
CAC 407,804.8714.600.19%
DAX 4024,304.4619.12-0.08%
Dow JONES (US)42,762.87443.131.05%
FTSE 1008,837.9126.870.30%
HKSE23,792.54114.43-0.48%
NASDAQ19,529.95231.511.20%
Nikkei 22537,741.61187.120.50%
NZX 50 Index12,563.4813.67-0.11%
S&P 5006,000.3661.061.03%
S&P/ASX 2008,515.7023.20-0.27%
SSE Composite Index3,385.361.260.04%

Market Movers